These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25258717)

  • 1. The role of microRNAs in diabetic nephropathy.
    Wu H; Kong L; Zhou S; Cui W; Xu F; Luo M; Li X; Tan Y; Miao L
    J Diabetes Res; 2014; 2014():920134. PubMed ID: 25258717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA: A new generation therapeutic target in diabetic nephropathy.
    Dewanjee S; Bhattacharjee N
    Biochem Pharmacol; 2018 Sep; 155():32-47. PubMed ID: 29940170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic modifications in the pathogenesis of diabetic nephropathy.
    Reddy MA; Tak Park J; Natarajan R
    Semin Nephrol; 2013 Jul; 33(4):341-53. PubMed ID: 24011576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone lysine methylation in diabetic nephropathy.
    Sun GD; Cui WP; Guo QY; Miao LN
    J Diabetes Res; 2014; 2014():654148. PubMed ID: 25215303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetics in the pathogenesis of diabetic nephropathy.
    Li X; Lu L; Hou W; Huang T; Chen X; Qi J; Zhao Y; Zhu M
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):163-172. PubMed ID: 35130617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
    Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
    BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs.
    Sankrityayan H; Kulkarni YA; Gaikwad AB
    Pharmacol Res; 2019 Mar; 141():574-585. PubMed ID: 30695734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment.
    Yarahmadi A; Shahrokhi SZ; Mostafavi-Pour Z; Azarpira N
    Biochem Pharmacol; 2021 Jul; 189():114301. PubMed ID: 33203517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNAs; powerful microRNA sponges to overcome diabetic nephropathy.
    Mafi A; Yadegar N; Salami M; Salami R; Vakili O; Aghadavod E
    Pathol Res Pract; 2021 Nov; 227():153618. PubMed ID: 34649056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs and the glomerulus.
    Kato M; Park JT; Natarajan R
    Exp Cell Res; 2012 May; 318(9):993-1000. PubMed ID: 22421514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Regulations in Diabetic Nephropathy.
    Lu Z; Liu N; Wang F
    J Diabetes Res; 2017; 2017():7805058. PubMed ID: 28401169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of expression of different microRNAs on insulin secretion and diabetic nephropathy progression.
    Mafi A; Aghadavod E; Mirhosseini N; Mobini M; Asemi Z
    J Cell Physiol; 2018 Jan; 234(1):42-50. PubMed ID: 30078212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Histone Modifications Involved in Profibrotic Gene Regulation by 12/15-Lipoxygenase and Its Oxidized Lipid Products in Diabetic Nephropathy.
    Yuan H; Reddy MA; Deshpande S; Jia Y; Park JT; Lanting LL; Jin W; Kato M; Xu ZG; Das S; Natarajan R
    Antioxid Redox Signal; 2016 Mar; 24(7):361-75. PubMed ID: 26492974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epigenetic regulators for treating diabetic nephropathy.
    Kushwaha K; Garg SS; Gupta J
    Biochimie; 2022 Nov; 202():146-158. PubMed ID: 35985560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.
    Kato M; Natarajan R
    Ann N Y Acad Sci; 2015 Sep; 1353(1):72-88. PubMed ID: 25877817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective.
    Zheng W; Guo J; Liu ZS
    Clin Epigenetics; 2021 Apr; 13(1):87. PubMed ID: 33883002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.
    Zanchi C; Macconi D; Trionfini P; Tomasoni S; Rottoli D; Locatelli M; Rudnicki M; Vandesompele J; Mestdagh P; Remuzzi G; Benigni A; Zoja C
    Diabetologia; 2017 Jun; 60(6):1114-1125. PubMed ID: 28364255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10.
    Sayyed SG; Gaikwad AB; Lichtnekert J; Kulkarni O; Eulberg D; Klussmann S; Tikoo K; Anders HJ
    Nephrol Dial Transplant; 2010 Jun; 25(6):1811-7. PubMed ID: 20067909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes.
    Komers R; Mar D; Denisenko O; Xu B; Oyama TT; Bomsztyk K
    Lab Invest; 2013 May; 93(5):543-52. PubMed ID: 23508046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy.
    Simpson K; Wonnacott A; Fraser DJ; Bowen T
    Curr Diab Rep; 2016 Mar; 16(3):35. PubMed ID: 26973290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.